About the Company
alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALIM News
Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call Transcript March 7, 2024 Alimera Sciences, Inc. isn’t one of the 30 most popular stocks among hedge ...
Buy Rating Affirmed for Alimera Sciences Amid Strong Financial Performance and Promising Clinical Trials
Alimera (ALIM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H.C.
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Net Revenues up 88% to $26.3 million vs. Q4 20222023 Net Revenues up 49% to $80.8 million vs. 2022Increases 2024 Revenue GuidanceATLANTA, ...
Alimera Sciences: Q4 Earnings Snapshot
ALPHARETTA, Ga. — ALPHARETTA, Ga. — Alimera Sciences Inc. (ALIM) on Thursday reported a loss of $3.8 million in its fourth quarter. The Alpharetta, Georgia-based company said it had a loss of 7 cents ...
Alimera Sciences price target raised by $1 at H.C. Wainwright, here's why
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual ...
Mizuho downgrades Amylyx to Neutral after ALS trial setback
Mizuho has lowered its recommendation on Amylyx ( NASDAQ: AMLX ), downgrading it from Buy to Neutral while cutting its 12-month price target to $4 from $32. The downgrade comes after the company ...
Alimera Sciences Inc (ALIM) Reports Significant Revenue Growth in Q4 and Full Year 2023
Increased by 88% to $26.3 million compared to Q4 2022. 2023 Full Year Net Revenue: Grew by 49% to $80.8 million versus the ...
Dry Age-Related Macular Degeneration Size, Share | Growth Report 2031
Age-related macular degeneration (AMD) disease causes the small central retinal macula of the eye to deteriorate. A crucial retina component is the ...
Ayr Wellness reports mixed Q4 results; initiates Q1 FY24 outlook
Q4 GAAP EPS of -$0.36 misses by $0.08. Revenue of $114.84M (+0.5% Y/Y) beats by $0.38M. AYR ended the year with a cash balance of $50.8 million.
Global Ocular Drug Delivery System Industry Gains Momentum, Expected to Reach US$ 31,410.2 Million by 2033 | According to FMI Report
The Global Ocular Drug Delivery System Industry is poised for transformative growth, with projections indicating it will ...
Hong Kong to Name Ex-KPMG China Head Carlson Tong to Chair Stock Exchange
The Hong Kong government plans to name Carlson Tong, the former chairman of KPMG China, to preside over the city’s stock exchange. Most Read from BloombergChemical Linked to Cancer Found in Acne ...
Q4 2023 Alimera Sciences Inc Earnings Call
Rick Eiswirth; President and Chief Executive Officer; Alimera Sciences Inc ...
Loading the latest forecasts...